Suma Heart Clinic, Tokyo, Japan.
Ann Cardiothorac Surg. 2013 Jul;2(4):493-8. doi: 10.3978/j.issn.2225-319X.2013.06.04.
The right gastroepiploic artery (GEA) has been recognized as a suitable and reliable conduit for coronary bypass surgery. From a sizable number of experiences, we know the use of this artery does not increase surgical risk, and no gastric ischemia nor abdominal complications occur with takedown of the GEA. This artery undergoes less significant arteriosclerosis and demonstrates physiological adaptability as seen in the internal thoracic artery (ITA). From our experience with over 1,500 GEA grafts, the operative mortality was 1.26%, and 5-, 10-, and 15-year survival rates were 91.7%, 81.4%, and 71.3% respectively, while the cardiac death-free survival rates were 95.8%, 91.7%, and 88.6%, respectively. The cumulative patency rate of the GEA graft was 98.5% at 1 month, 93.7% at 1 year, 86.2% at 5 years, and 70.2% at 10 years. The GEA graft is a safe and effective arterial conduit for coronary artery bypass grafting (CABG).
胃网膜右动脉(GEA)已被认为是冠状动脉旁路移植术的一种合适且可靠的移植物。从大量经验中我们知道,使用这种动脉并不会增加手术风险,在取下 GEA 时也不会发生胃缺血或腹部并发症。与内乳动脉(ITA)一样,该动脉的动脉硬化程度较轻,且具有生理适应性。我们的经验涉及 1500 多个 GEA 移植物,手术死亡率为 1.26%,5 年、10 年和 15 年的生存率分别为 91.7%、81.4%和 71.3%,而无心脏死亡生存率分别为 95.8%、91.7%和 88.6%。GEA 移植物的 1 个月、1 年、5 年和 10 年累积通畅率分别为 98.5%、93.7%、86.2%和 70.2%。GEA 移植物是冠状动脉旁路移植术(CABG)安全有效的动脉移植物。